Title : LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells.

Pub. Date : 2021

PMID : 33628103






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Background: Sorafenib, an oral multi-kinase inhibitor of rapidly accelerated fibrosarcoma; vascular endothelial growth factor receptor-2/3, platelet-derived growth factor receptor, c-Kit, and Flt-3 signaling, is approved for treatment of advanced hepatocellular carcinoma (HCC). Sorafenib kinase insert domain receptor Homo sapiens